Moreover, the PAM50 ROR was able to predict which patients with early stage breast cancer,, ER positive/ HER-2 negative, node-positive breast cancer could be safely treated with adjuvant hormonal therapy only as well as those who could benefit from chemotherapy [18]. This evidence concerns the gene ESR1 and breast cancer.